Gastrointestinal Alterations
|
|
- Herbert Moody
- 5 years ago
- Views:
Transcription
1 Gastrointestinal Alterations Nancy Thompson, RN, MS, AOCNS Swedish Cancer Institute Nausea & Vomiting Mucositis Taste Alterations Anorexia / Cachexia GI Alterations The Chinese do not draw any distinction between food and medicine. Lin Yutang Case Study: Sarah Hogan A 44 year old female, diagnosed with extensive stage small cell lung cancer. She is told by her oncologist that she will be receiving etoposide 100 mg/m 2 and cisplatin 100 mg/m 2. She is worried about side effects because she had a friend who had a lot of nausea and vomiting. 1
2 Therapy-Related Emesis Patterns Anticipatory: Occurs before or during treatment from associated stimuli; a conditioned response > 25% incidence Acute: Occurs within 24 hours > Incidence determined by agents CINV: Prevalent With Common Regimens Even Today Despite 5-HT3 Use Site of Cancer Breast Lung Regimen Vomiting Nausea TAC 44.5% 80.5% Carboplatin + paclitaxel 33.3% 44.3% Delayed: Occurs at least 24 hours after therapy and may persist up to 6 days > Cisplatin associated with highest incidence Colorectal Ovarian FOLFOX 6 42% 67% Carboplatin + docetaxel 37% 78% TAC=docetaxel + doxorubicin + cyclophosphamide; FOLFOX 6=oxaliplatin + leucovorin + 5-fluorouracil. Risk Factors for CINV: Chemotherapy-Specific Factors Use of moderately or highly emetogenic regimens, such as: > Cisplatin-based regimens > Cyclophosphamide-based regimens (e.g. CHOP) > AC (anthracycline + cyclophosphamide) > Carboplatin-based regimens > ABVD (doxorubicin + bleomycin + vinblastine + dacarbazine) > FOLFOX/FOLFIRI (oxaliplatin + leucovorin + 5FU/irinotecan + leucovorin + 5FU) Short IV infusion time Repeated cycles of chemotherapy Female Age < 50 years Risk Factors for CINV: Patient Characteristics History of low alcohol intake (<1.5 oz/day) History of motion sickness History of morning sickness during pregnancy History of prior CINV Extreme anxiety Other factors > pain, constipation, medications Hesketh PJ. Oncologist. 1999;4: Navari RM. J Support Oncol. 2003;1: NCCN Guidelines. v : antiemesis. Navari RM. J Support Oncol. 2003;1:
3 Classification of Acute Emetogenic Potential of Single Chemotherapeutic Agents Single Chemotherapeutic Agents With Highest Potential for Acute Emesis Level 5 Emesis in > 90% of patients Level Frequency of Emesis Agent Level 4 Level 3 Emesis in 60% - 90% of patients Emesis in 30% - 60% of patients 5 > 90% Carmustine > 250 mg/m 2 Cisplatin >= 50 mg/m 2 Cyclophosphamide > 1,500 mg/m 2 Dacarbazine Mechlorethamine Streptozocin Level 2 Level 1 Emesis in 10% - 30% of patients Emesis in < 10% of patients 4 60% - 90% Carboplatin Carmustine <= 250 mg/m 2 Cisplatin < 50 mg/m 2 Cyclophosphamide > 750 mg/m2 <= 1,500 mg/m 2 Cytarabine > 1 g/m 2 Doxorubicin > 60 mg/m 2 Methotrexate > 1,000 mg/m 2 Procarbazine (oral) Adapted from Hesketh PJ et al. J Clin Oncol. 1997;15: , 1997, with permission from the American Society of Clinical Oncology. Adapted from Hesketh PJ et al. J Clin Oncol. 1997;15: , 1997, with permission from the American Society of Clinical Oncology. Single Chemotherapeutic Agents With Moderate Potential for Acute Emesis Both Peripheral and Central Pathways Play a Role in CINV Level Frequency of Emesis Agent 3 30% - 60% 2 10% - 30% Cyclophosphamide < 750 mg/m 2 Cyclophosphamide (oral) Doxorubicin mg/m 2 Epirubicin < 90 mg/m 2 Idarubicin Ifosfamide Irinotecan Methotrexate 250 1,000 mg/m 2 Mitoxantrone <15 mg/m 2 Capecitabine Docetaxel Etoposide 5-FU <1,000 mg/m 2 Gemcitabine Methotrexate >50 <250 mg/m 2 Mitomycin Paclitaxel Topotecan b Neurokinin-1 Adapted from Hesketh PJ et al. J Clin Oncol. 1997;15: , 1997, with permission from the American Society of Clinical Oncology. 1. Tavorath R et al. Drugs. 1996;52: Grunberg SM, Hesketh PJ. N Engl J Med. 1993;329(24): Illustration by Kirk Moldoff. 3
4 Nausea & Vomiting Pharmacologic Management ONS: Putting Evidence into Practice Prevention, prevention, prevention!! Select appropriate antiemetic based on treatment regimen Consider cumulative effects Administer through entire anticipated period of nausea & vomiting Oral and IV antiemetics have equivalent effectiveness Consider other potential causes of emesis Serotonin Antagonists Indications: > High & moderate to high emetogenic chemotherapy Common side effects: > Headache, diarrhea, constipation, fever Examples: > ondansetron, granisetron, dolasteron > Palonosetron (2 nd generation) NK-1 Antagonist Indications: > Acute and delayed nausea / vomiting > Highly emetogenic chemotherapy Common side effects: > Diarrhea, hiccups, fatigue Examples: > Aprepitant (oral) > Fosaprepitant (IV) 4
5 CINV Cheat Sheet Phase of CINV Acute Events Delayed Events Mechanism of Action Peripheral Pathway Central Pathway Neurotransmitter Serotonin Substance P Class of Drug Drug Examples 5HT 3 Receptor Antagonist Dolasetron, Granisetron, Ondansetron, Palonsetron NK 1 Receptor Antagonist Aprepitant Fosaprepitant Case Study: Sarah Hogan Sarah has completed two cycles of her etoposide/cisplatin and comes into the clinic. As part of your nursing assessment, you use a gloved finger and a pen light to carefully look in her mouth. Mucositis Grading Grade Criteria 0 None I Oral soreness, erythema II Oral erythema, ulcers, solid diet tolerated III Oral ulcers, liquid diet only IV Oral alimentation impossible Courtesy of BB Toth, MD Anderson 5
6 Initiation Radiation Chemotherapy Pathobiology of Mucositis Upregulation & Message Gen Signaling & Amplification Ulceration Healing Risk Factors for Oral Mucositis Patient-related > Age > Gender > Body Mass Index > Renal Function > Hematologic malignancy > Genetic factors > Previous cancer therapy > Oral health and hygiene > Xerostomia Patient-related > Poorly fitting dental appliances > Smoking 0-21 Days Based on: Sonis S. (2003); Sonis S. (2004); Reprinted with permission from The Curry Rockefeller Group, LLC, Cancer Therapy-Induced Oral Mucositis, Köstler et al. (2001). Risk Factors for Oral Mucositis Patient-related Age Gender Body mass index Renal function Hematologic malignancy Genetic factors Previous cancer therapy Oral health and hygiene Xerostomia Patient-related Poorly fitting dental appliances Smoking actinomycin D amsacrine bleomycin cytarabine daunorubicin docetaxel doxorubicin etoposide Agents Most Commonly Associated with Mucositis floxuridine 5-fluorouracil methotrexate mitoxantrone plicamycin thioguanine vinblastine vindesine 6
7 Impact of Oral Mucositis Clinical Consequences > Dose reduction > Dose/Treatment delay > Morbidity increase fever, increase infection > Mortality 4 fold increase in risk Economic > Increase resource utilization > Increase cost -- $4,500 per day Mucositis: Assessment Subjective: > pain, burning, increased sensitivity, altered taste Objective: > erythema, ulceration, saliva, bleeding, cracked lips, hoarse voice Functional: > Ability to chew, difficulty swallowing or speaking Systematic oral assessment at least daily or at each patient visit Sonis et al. (2001); Ruescher, et al. (1998); Elting et al. (2003). ONS Putting Evidence Into Practice, 2009 Prevention > Collaborate with a multidisciplinary team > Oral care products Mucositis: Management > Patient education (written, verbal, demonstration) > Treat dental problems before cytotoxic therapy > High protein diet > Fluid intake > 1500 ml/day > Cryotherapy for bolus 5-FU Treatment > Oral agents & hygiene > Systemic pain medications > Culture lesions Mucositis: Oral Hygiene Program Routine oral care protocol > Daily oral self-exam, report signs of mucositis > Oral hygiene after each meal and at bedtime, increase to q 2 hours as needed > Floss daily with dental tape > Brush with soft toothbrush, 90 seconds bid > Swish after each meal, at bedtime, at other times with water or mouth rinse (Normal Saline, sodium bicarbonate) Avoid oral irritants including tobacco and alcohol Maintain adequate hydration Use water based moisturizers to protect the lips ONS Putting Evidence Into Practice,
8 Magic Mouthwash Pro-Self Mouth Aware Program Randomized Double-blind, Placebo-controlled study 23 outpatient settings, 142 patients No differences in effectiveness among 3 groups in outcome (pain relief or time to resolution) Salt and soda rinses were least costly Magic Mouthwash Chlorhexidine Salt/Soda Rinses 2 tsp baking soda 1 tsp salt 1 liter of water Salt and Soda Rinse Rinse oral cavity every 2-4 hours or more often as needed. Make a fresh solution every 24 hours. Dodd MJ, Dibble SL, Miaskowski C, et al.. (2000). Cryotherapy for Bolus Mucotoxic Chemotherapy with Short Half Life Bolus 5-fluorouracil (5-FU) & Melphalan Instruct patients to hold ice chips in their mouth starting 5 minutes prior and for 30 minutes after. The effectiveness of this intervention is based on vasoconstriciton of the circulation in the oral cavity and the short half life of these agents. Evidence is lacking to support the benefit with other chemotherapy agents. Do not use in patients receiving oxaliplatin. Case Study: Sarah Hogan Sarah complains that food does not taste the same and that everything tastes like cardboard, especially red meat. She asks you if this is normal. ONS Putting Evidence Into Practice,
9 Taste Alterations: Defined An actual or perceived change in taste sensation or loss of taste > Hypogeusethesia: A decrease in the acuity of the taste sensation > Dysgeusia: An unusual taste perception, perceived as unpleasant > Ageusia: An absence of the taste sensation, mouth blindness True or False? (Hint: Only one is true) 1. Taste changes associated with chemotherapy often resolve once therapy is completed. 2. Approximately one in three cancer patients receiving chemotherapy report taste changes. 3. The most commonly reported intervention to manage metallic taste is to ingest sour candies. 4. Metallic taste changes are often reported with platinum-based chemotherapy regimens. Taste Alterations: Causes Taste Alterations: Consequences Disease related > Invasion of the tumor > Oral infections > Excretion of amino acid-like substances from the tumor cells Treatment related > Specific surgical sites > Radiation > Chemotherapy: Lowered threshold for bitter taste Increased threshold for sweet, sour and salty taste Aversion to meats Metallic taste Anorexia/poor appetite Decreased oral intake Reduced energy levels Poor quality of life Altered or perverted sense of taste for certain foods * Can persist for hours, weeks or months after treatment 9
10 Taste Alterations: Management Experiment with spices and flavorings Use the aroma of foods to stimulate taste Encourage oral hygiene before and after meals Add increased sweeteners Substitute other sources of protein (non-meat) Marinate meats in sweet marinades Avoid the sight and smell of foods causing unpleasantness Avoid alcohol, commercial mouthwashes, smoking Consume hard candies and / or chew gum to change taste before meals and before chemotherapy treatment to reduce metallic taste Use plastic eating utensils to manage the metallic taste Refer to dietitians for nutritional counseling Assess for weight loss Case Study: Sarah Hogan Before beginning her 4th cycle of etoposide/cisplatin, Sarah comes in to the clinic for her assessment. You notice that she has lost 15 pounds since her baseline weight. She tells you that she has no appetite. Common Nutritional Challenges Anorexia: Defined Anorexia Malnutrition Weight Loss Muscle mass loss Cachexia At diagnosis: 50% of patients present with nutritional issues Malnutrition is the most common secondary diagnosis to cancer Involuntary loss of appetite accompanied by decreased food intake Often accompanied by weight loss May be insidious and may only be obvious by weight loss Can lead to cachexia Often is not treated or diagnosed 10
11 Malnutrition: Defined A state of nutrition in which a deficiency, excess or imbalance of energy, protein, and other nutrients causes measurable adverse effects on body function and clinical outcome. Anorexia and Malnutrition: Causes Physiologic: Concurrent symptoms > Nausea/vomiting > Early satiety > Pain > Dysphagia > Mucosisits > Ascites > Fatigue Structural problems > Abdominal tumors > Surgical and dental changes Medications > Narcotics, iron, antibiotics Psychological > Anxiety, depression > Loss of pleasure associated with food Social factors > Companionship > Eating environment > Issues associated with food preparation Cachexia: Defined A multifactorial syndrome characterized by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment 1. Pre-cachexia - Weight loss of less than 5%. Anorexia and metabolic change 2. Cachexia - Weight loss of more than 5% or BMI less than 20 and weight loss greater than 2% or sarcopenia and weight loss more than 2%. Reduced food intake and systemic inflammation. Patients with weight loss have worse outcomes Chemotherapy dose reductions Increase dose limiting toxicity Decreased treatment response Decreased quality of life and performance status Shorter survival 3. Refractory Cachexia Variable degree of cachexia. Cancer disease both pro-catabolic and not responsive to anticancer treatment. Low performance status. Less than 3 months expected survival. Fearon K., Lancet Oncol. 2011; 12(5) ) Andreyev HJN, Eur J Cancer, 1998/34(4)
12 Malnutrition s Effect on Oncology Patients Malnourished cancer patients do not live as long as their counterparts who remain well nourished Just a small loss of weight may be a sign of a nutritional decline that leads to: > Treatment Delays > Complications > More frequent hospitalizations > Reduced key outcomes such as quality of life Dewys, WD et al. Am J Med, 1980, 69: Dewys, WD et al. Am J Med, 1980, 69: Early Assessment and Intervention is Critical Laboratory Results Dietary factors > Diet history > Ability to purchase & prepare food > Food preferences / aversions > Calorie count / food diary > Educational needs Physical Exam > Weight loss > Functional status Laboratory Data > Pre-albumin, albumin, transferrin Serum albumin > Measures visceral protein stores > Less than 3.5 g/dl shows recent protein depletion Serum prealbumin > Less than 15 mg/dl > Indicates protein depletion Serum transferrin > Less than 200 mg/dl > Reflects a decrease in the body s ability to make serum proteins 12
13 Anorexia / Cachexia: Management Treat the tumor (keep patients on treatment!) Early and regular assessment (weight % and time) Early intervention prior to a crisis Manage anorexia causes (N & V, Mucositis, pain) Consider appetite stimulants > Corticosteroids, progestins Consider nutritional supplements with Revigor > Ensure clinical Strength or Juven Dietary Counseling Non-pharmacological > small, frequent meals, oral hygiene, exercise, high calorie, high protein foods & supplements Recommended Appetite Stimulants Corticosteroids: Prednisolone, Dexamethasone > Improve appetite, food intake, sense of well-being and performance status > Most effective type, dose or route not established > Benefit is significant yet short in duration > Long term use is associated with significant toxicities Megestrol acetate (Megace) mg daily > Most widely studied > Dose related benefit on appetite, caloric intake and body weight and sensation of well-being. > Not to be used in patients at risk for thromboembolic disease, heart disease or serious fluid retention Individualized Dietary Counseling Non-pharmacological Improved nutritional intake and body weight Reduction in the incidence of anorexia Improved quality of life Exercise/strength training - improved lean muscle mass Refer to cancer rehabilitation or PT One of the most effective things we can do! PUTTING EVIDENCE INTO PRACTICE,
14 Nutritional Alterations Nausea & Vomiting Mucositis Taste Alterations Anorexia / Cachexia 14
Symptom Management of Gastrointestinal Alterations
Symptom Management of Gastrointestinal Alterations Parisa Tsutsumi RN, BSN, OCN, BMTCN University of Washington Medical Center Nausea and Vomiting Mucositis Taste Alterations Gastrointestinal Alterations
More informationNausea and Vomiting. Symptom Management of Gastrointestinal Alterations. Gastrointestinal Alterations. Nausea/Vomiting Patterns
Symptom Management of Gastrointestinal Alterations Elise Frans, MN, RN, CWON Oncology Clinical Nurse Specialist University of Washington Medical Center delterzo@uw.edu Nausea and Vomiting Mucositis Taste
More informationNutritional Alterations
Nutritional Alterations Nutritional Alterations Nancy Thompson, RN, MS, AOCNS Swedish Cancer Institute Diarrhea Constipation Nausea & Vomiting Mucositis Taste Alterations Anorexia / Cachexia GI Symptoms
More informationMASCC Guidelines for Antiemetic control: An update
MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,
More informationGUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION
GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY More than half of all cancer patients experience nausea or vomiting during the course of their treatment. If nausea or vomiting becomes severe enough,
More informationGuidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients
Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For
More informationWest of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting
West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial
More informationGuideline Update on Antiemetics
Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction
More informationDRUG EXTRAVASATION. Vesicants. Irritants
DRUG EXTRAVASATION Vesicants Irritants Vesicants Antineoplastic drugs Amsacrine Dactinomycin Daunorubicin Docetaxel (rare) Doxorubicin Epirubicin Idarubicin Mechlorethamine Mitomycin Oxaliplatin (rare)
More informationSubject: Fosnetupitant-Palonosetron (Akynzeo) IV
09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationDefining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice
Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice PAUL J. HESKETH St. Elizabeth s Medical Center, Boston, Massachusetts, USA Key Words. Chemotherapy Emesis Emetogenicity
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationNeoplastic Disease KNH 406
Neoplastic Disease KNH 406 Cancer Carcinogenesis - Etiology Genes may be affected by antioxidants, soy, protein, fat, kcal, alcohol Nutritional genomics study of genetic variations that cause different
More informationSubject: Palonosetron Hydrochloride (Aloxi )
09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationNorthern Cancer Alliance
Northern Cancer Alliance Anti-emetic Guidelines for Chemotherapy Induced Nausea and Vomiting (CINV) Adult Oncology & Haematology Document Control Document Title: Antiemetic Guidelines for CINV NESCN v2.2
More informationManaging Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting
Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe
More informationUpdates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017
Updates in Chemotherapy-Induced Nausea and Vomiting (CINV) 2017 MELISSA C. MACKEY, PHARMD, BCPS, BCOP ONCOLOGY CLINICAL PHARMACIST DUKE UNIVERSITY HOSPITAL AUGUST 5, 2017 Objectives Review risk factors
More informationChemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines
North of England Cancer Network Chemotherapy Induced Nausea and Vomiting (CINV) Anti-emetic Guidelines Adult Oncology & Haematology Quality and safety for every patient every time For more information
More informationSubject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )
09-J2000-60 Original Effective Date: 06/15/16 Reviewed: 04/11/18 Revised: 01/01/19 Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT
More informationEmetogenicity level 1. Emetogenicity level 2
Emetogenicity level 1 15 mins Pre-Chemo Maxalon 10mg po During chemo and Post Chemo 3 days Maxalon10mg po 8 hourly Increase Maxalon 20mg po 8 hourly Change to Cyclizine 50mg po 8 hourly 3 days If nausea
More informationCorporate Medical Policy
Antiemetic Injection Therapy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: antiemetic_injection_therapy 5/2015 3/2017 3/2018 3/2017 Description of Procedure
More informationEssentials. Oncology Practise Essentials. Oncology Basics. Tutorial 5. Toxicity of Chemotherapy Agents
Toxicity of This tutorial reviews the common clinical toxicities of chemotherapy gastrointestinal, dermatological, secondary malignancies, and infertility and their treatment and management. Goals and
More informationChemotherapy Induced Nausea and Vomiting
Chemotherapy Induced Nausea and Vomiting Aminah Jatoi, M.D. Professor of Oncology Mayo Clinic Rochester, Minnesota April 27, 2017 clinical and biologic fundamentals of chemotherapy induced nausea and vomiting
More informationExhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A
More informationJob title: Consultant Pharmacist/Advanced Practice Pharmacist
Title : Guidelines for the Use of Antiemetics Purpose: To provide trust-wide guidance on the safe and effective use of antiemetics for the prevention and treatment of chemotherapy and radiotherapy induced
More informationClinical Tools and Resources for Self-Study and Patient Education
Clinical Tools and Resources for Self-Study and Patient Education CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING CLINICIAN'S RESOURCE GUIDE The clinical tools and resources contained herein are provided as educational
More informationClinical Policy: Dolasetron (Anzemet) Reference Number: ERX.NPA.83 Effective Date:
Clinical Policy: (Anzemet) Reference Number: ERX.NPA.83 Effective Date: 09.01.18 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationManagements of Chemotherpay Induded Nausea and Vomiting
REVIEW ARTICLE Managements of Chemotherpay Induded Nausea and Vomiting Department of Surgery, The Catholic University of Korea Sung Geun Kim 23 24 Sung Geun Kim Korean Journal of Clinical Oncology Summer
More informationClinical Policy: Nabilone (Cesamet) Reference Number: ERX.NPA.35 Effective Date:
Clinical Policy: (Cesamet) Reference Number: ERX.NPA.35 Effective Date: 09.01.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationATTUALITÀ NEL CONTROLLO DELL EMESI
ATTUALITÀ NEL CONTROLLO DELL EMESI Dr Claudio Lotesoriere Dipartimento di Oncoematologia S.C. di Oncologia Medica P.O. San G. Moscati TARANTO email oncologia.taranto@gmail.com Types of CINV: Definitions
More informationPrevention and Management of chemo-and radiotherapy-induced nausea and vomiting
Prevention and Management of chemo-and radiotherapy-induced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University of Heidelberg
More informationNutrition, Radiation and Brain Cancer
Oncology Nutrition Nutrition, Radiation and Brain Cancer Why is nutrition important? Eating well can help you: Maintain your weight, strength, and energy Heal wounds and repair tissues after treatment
More informationSystemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients
Systemic Anti-cancer Therapy Care Pathway Guidelines for the management of SACT induced nausea and vomiting in adult patients Pathway of Care Kent & Medway Cancer Collaborative Publication date June 2018
More informationMedicare Part C Medical Coverage Policy
Medicare Part C Medical Coverage Policy Oral Antiemetic Medications Origination: June 17, 2009 Review Date: May 17, 2017 Next Review: May, 2019 DESCRIPTION OF PROCEDURE OR SERVICE Oral antiemetic medications
More informationChemotherapy induced emesis: Are we doing are best? David Warr University of Toronto
Chemotherapy induced emesis: Are we doing are best? David Warr University of Toronto david.warr@uhn.on.ca Conflict of interest Merck: speakers bureau and consultant Eisai: consultant Outline What is the
More informationSCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders
1.0 Introduction The (SCI) is a not-for-profit collaboration between the Hospital for Sick Children (SickKids), Toronto, Canada, and seven Caribbean health care institutions across six countries that strive
More informationCHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING Jennifer Shamai MS, RN, AOCNS, BMTCN Professional Practice Leader Department of Clinical Practice And Professional Education Click How to the edit Experts Master
More informationMOLECULAR AND CLINICAL ONCOLOGY 2: , 2014
MOLECULAR AND CLINICAL ONCOLOGY 2: 375-379, 2014 Palonosetron exhibits higher total control rate compared to first generation serotonin antagonists and improves appetite in delayed phase chemotherapy induced
More informationClinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zuplenz) Reference Number: CP.PMN.45 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationStandard Operating Procedure for the Prevention and Treatment of Oral Mucositis
the Prevention and Treatment of Oral Mucositis Lead Author/Co-ordinator: Lisa MacLeod Specialist Clinical Pharmacist Haem/Onc UK Oral Mucositis in Cancer Group Signature: Reviewers: NCAG Signature: Approver:
More informationNausea and Vomiting Team. Outcome: Nausea and Vomiting. Scope of the Problem. Definition: Nausea
Nausea and Vomiting: The Continuing Battle to Improve Outcomes Jan Tipton, MSN, RN, AOCN Oncology CNS Medical University of Ohio Toledo, Ohio jtipton@meduohio.edu Nausea and Vomiting Team Jan Tipton, MSN,
More informationCommittee Approval Date: December 12, 2014 Next Review Date: July 2015
Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:
More informationNutrition for Cancer. Nutrition for Cancer. Patients. Geoffrey Axiak. Clinical Nutrition Nurse Mater Dei Hospital
Nutrition for Cancer Nutrition for Cancer Patients Geoffrey Axiak Clinical Nutrition Nurse Mater Dei Hospital Change in Energy Expenditure in Change in Energy Expenditure in Disease (Northwestern University
More informationAntiemetics: Guidelines, Interactions and more.
Antiemetics: Guidelines, Interactions and more. Chemotherapy-induced side effects -the patient s view Loss of hair The thought of coming for chemo Affects family/partner Affects work/home duties Jude Lees
More informationNutrition, Radiation Therapy and Brain Cancer
Nutrition, Radiation Therapy and Brain Cancer Why is nutrition important? Eating well can help you: Maintain your weight, strength, and energy Heal wounds and repair tissues after treatment Support your
More informationRolapitant (Varubi) A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Rolapitant (Varubi) A Substance P/Neurokinin-1 Receptor Antagonist for the Prevention of Chemotherapy-Induced Nausea and Vomiting Tamara Goldberg, PharmD, BCPS; Brooke Fidler, PharmD; and Stephanie Cardinale,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Anzemet) Reference Number: CP.PMN.141 Effective Date: 09.01.06 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationShort-Term Side Effects from Head and Neck Radiation
PATIENT EDUCATION patienteducation.osumc.edu Short-Term Side Effects from Head and Neck Radiation Side effects are problems caused by radiation therapy. These problems are different for each person and
More informationDrug: Aprepitant (Emend ) Date of Review: 4/01/10
CAMBRIDGESHIRE JOINT PRESCRIBING GROUP Business Case Evaluation and Recommendation Document Drug: Aprepitant (Emend ) Date of Review: 4/01/10 Business Case Decision and date: DOUBLE RED, 20 January 2010
More informationClinical Policy: Aprepitant (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17
Clinical Policy: (Emend) Reference Number: CP.PMN.19 Effective Date: 11/06 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Cesamet) Reference Number: CP.PMN.160 Effective Date: 11.16.16 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationSupportive care session 1:
Board review in oncology pharmacy 2013 Managing Disease or Treatment Related Complication Supportive care session 1: Chemotherapy induced-nausea and vomiting Suthan Chanthawong, B. Pharm, RPh. Objectives
More informationAPPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer
APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer 5850/5980 University Avenue, PO Box 9700, Halifax, N.S. B3K 6R8 PEDIATRIC HEMATOLOGY/ONCOLOGY
More informationComparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens
569 Ivyspring International Publisher Research Paper Journal of Cancer 2016; 7(5): 569-575. doi: 10.7150/jca.13637 Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk
More informationFor the Patient: Mitoxantrone Other names:
For the Patient: Mitoxantrone Other names: Mitoxantrone (mite-oh-zan-trone) is a drug that is used to treat many types of cancer. It is a blue liquid that is injected into a vein. Tell your doctor if you
More informationOral Complications of Chemotherapy and Head/Neck Radiation
Oral Complications of Chemotherapy and Head/Neck Radiation By Marietta T. Farrell, RN, BSN The contents of this course are taken from the National Cancer Institute, NIH. Learning objectives and post test
More informationPrevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients
Prevention of Antineoplastic Medication induced Nausea and Vomiting in Pediatric Cancer Patients Done by :Meznah Zaid Al-Mutairi Pharm.D Candidate PNU University College of Pharmacy Introduction Nausea
More informationTRANSPARENCY COMMITTEE OPINION. 31 January Date of marketing authorisation: 22 March 2005 (centralised marketing authorisation)
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 31 January 2007 ALOXI 250 µg solution for injection B/1 CIP 375,482-8 Applicant: THERABEL LUCIEN PHARMA palonosetron
More informationMedication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC
Medication Review Cancer Chemotherapy Drugs Pharmacy Technician Training Systems Passassured, LLC Medication Review, Cancer Chemotherapy Drugs PassAssured's Pharmacy Technician Training Program Medication
More informationSystemic management of pancreatic cancer: Supportive care
Systemic management of pancreatic cancer: Supportive care Snežana Bošnjak @bosnjaksupport Institute for Oncology and Radiology of Serbia Serbia, Belgrade Supportive Care in Cancer The prevention & management
More informationUsing a Simple Diary for Management of Nausea and Vomiting During Chemotherapy
Using a Simple Diary for Management of Nausea and Vomiting During Chemotherapy Problem identification Nausea and vomiting (N&V) are frequent complications following chemotherapy, even when taking 5-HT3
More informationWhy Patients Experience Nausea and Vomiting and What to Do About It
Why Patients Experience Nausea and Vomiting and What to Do About It Rebecca Clark-Snow, RN, BSN, OCN The University of Kansas Cancer Center Westwood, Kansas Multiple Roles for Supportive Care in Cancer
More informationCurrent and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Objectives
Current and Emerging Therapeutic Options in the Management of Chemotherapy-Induced Nausea and Vomiting (CINV) Susan Urba, M.D. University of Michigan Comprehensive Cancer Center Objectives Mechanisms of
More informationGuideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients POGO Antineoplastic Induced Nausea and Vomiting Guideline Development Panel: L.
More informationPrevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting
Prevention and Management of cancer disease and of chemo-and radiotherapyinduced nausea and vomiting Focusing on the updated MASCC/ESMO guidelines Karin Jordan Department of Hematology and Oncology, University
More informationESMO HIGHLIGHTS SUPPORTIVE AND PALLIATIVE CARE
ESMO 2016 - HIGHLIGHTS SUPPORTIVE AND PALLIATIVE CARE FLORIAN SCOTTE Cancer Department Supportive Care in Cancer Unit Georges Pompidou European Hospital Paris France esmo.org DISCLOSURE SLIDE Consultant
More informationChapter 27 & 28. Key Terms. Digestive System. Fig. 27-1, p. 443 Also known as the Gastrointestinal System (GI system)
Chapter 27 & 28 Nutrition & Fluids Key Terms Aspiration Dehydration Edema Dysphagia Gastrostomy tube Intravenous therapy (IV) Digestive System Fig. 27-1, p. 443 Also known as the Gastrointestinal System
More informationChristine Batten DFM 484 Cast Study 31 Lymphoma Treated with Chemotherapy
Christine Batten DFM 484 Cast Study 31 Lymphoma Treated with Chemotherapy 1. What type of cancer is lymphoma? Lymphoma is cancer of the lymphatic system, a blood-forming cancer. 4. Generally, patients
More informationOCN REVIEW GASTROINTESTINAL FUNCTION & NUTRITIONAL ALTERATIONS. GI Function & Nutritional Alterations. Symptom Management: 19% Diarrhea.
Symptom Management: 19% OCN REVIEW Briana Sanger, MSN, RN, OCN Lenise Taylor, MN, RN, AOCNS, BMTCN Seattle Cancer Care AllianceUniversity of Washington Medical Center A. Etiology and patterns of symptoms
More informationDrug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc.
Drug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc. Pharmacology: Aprepitant (previously known as MK-0839 and L-754030) is a new molecular entity that is the first in a new therapeutic class,
More informationGI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics. Dr. Alia Shatanawi
GI Pharmacology -4 Irritable Bowel Syndrome and Antiemetics Dr. Alia Shatanawi 11-04-2018 Drugs used in Irritable Bowel Syndrome Idiopathic, chronic, relapsing disorder characterized by abdominal discomfort
More informationManagement of Nausea and Vomiting
June 01, 2015 By Rudolph M. Navari, MD, PhD, FACP [1] Although marked progress in controlling chemotherapy-induced emesis has occurred over the past 25 years, nausea and vomiting remain among the most
More informationThalidomide for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
Thalidomide for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy Geng Song, Qian He, Fanfan Li, and Nianfei Wang Department of Oncology, The Second Affiliated
More information9/3/2014. Conflict of Interest Disclosures. Learning Objectives. Definitions of Nausea/Vomiting. Definitions of Nausea/Vomiting
Conflict of Interest Disclosures LeAnn B. Norris Teva Pharmaceuticals Last Chance Webinar 2014 Oncology Supportive Care LeAnn B. Norris, PharmD, BCPS, BCOP Assistant Professor South Carolina College of
More informationOral Toxicity Timeline
Oral Mucositis Michael Schmitt, MD PhD Head Clinical Stem Cell Transplantation and Immunotherapy Department of Internal Medicine III University of Rostock Germany Oral Toxicity Timeline Injury Starts on
More informationDelayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only)
Support Care Cancer (2011) 19 (Suppl 1):S57 S62 DOI 10.1007/s00520-010-1039-y SPECIAL ARTICLE Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only) Fausto Roila & David
More informationDiet what helps? Lindsey Allan Macmillan Oncology Dietitian Royal Surrey County Hospital, Guildford
Diet what helps? Lindsey Allan Macmillan Oncology Dietitian Royal Surrey County Hospital, Guildford Diet and cancer Diet and cancer Nutrition research Lack of funding RCTs Low quality Small sample sizes
More informationChapter 20. Assisting With Nutrition and Fluids
Chapter 20 Assisting With Nutrition and Fluids Food and water: Are physical needs Basics of Nutrition Are necessary for life A poor diet and poor eating habits: Increase the risk for diseases and infection
More informationANTIEMETIC GUIDELINES: MASCC/ESMO
Open Issues for CINV Do we reliably measure that? Do we control nausea optimally? Are guidelines useful for oral therapies related nausea and vomiting? Breakthrough and refractory nausea and vomiting:
More informationMEDICAL NECESSITY GUIDELINE
PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationOral care during Radiotherapy to the head and neck region
Oral care during Radiotherapy to the head and neck region The Sussex Cancer Centre Information for patients Introduction This leaflet describes the effects radiotherapy can have when your mouth is included
More informationABOUT THIS MEDICATION What are these drugs used for? Docetaxel is an anticancer drug used to treat cancers in the area of the neck and throat.
For the Patient: HNAVDOC Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck with docetaxel HN=Head and Neck AV=Advanced DOC=Docetaxel ABOUT THIS MEDICATION What are these drugs
More information1. Purpose Documentation Description.1 4. References 8 5. Cross-References.8 6. Development of the guideline.8
CLINICAL GUIDELINE For use in (clinical areas): For use by (staff groups): For use for (patients): Document owner: Status: Oncology/Haematology Unit (excluding Paediatrics) Oncologists, Haematologists,
More informationRenal Function and Associated Laboratory Tests
Renal Function and Associated Laboratory Tests Contents Glomerular Filtration Rate (GFR)... 2 Cockroft-Gault Calculation of Creatinine Clearance... 3 Blood Urea Nitrogen (BUN) to Serum Creatinine (SCr)
More informationIvyspring International Publisher. Introduction. Journal of Cancer 2017, Vol. 8. Abstract
1371 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(8): 1371-1377. doi: 10.7150/jca.17102 Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior
More informationInternational Symposium on Supportive Care in Cancer, MASCC/ISOO 2013, Berlin, Germany. What was hot at MASCC/ISOO Annual Meeting this year?
International Symposium on Supportive Care in Cancer, MASCC/ISOO 2013, Berlin, Germany What was hot at MASCC/ISOO Annual Meeting this year? Supportive Care Makes Excellent Cancer Care Possible. This slogan
More informationAntineoplastic Drugs. Antineoplastic Drugs. Herbal Alert. Pharmacology Chapter 51. Green tea
Antineoplastic Drugs Pharmacology Chapter 51 Carolyn Wright, RN, BSN Ford, S. & Roach, S. (2010). Roach's introductory clinical pharmacology (9 th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationSURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO. PARTECIPATE TUTTI nicsonet.it
SURVEY SUL CONFLITTO DI INTERESSE IN ONCOLOGIA PROMOSSO DAL CIPOMO 1-31 MARZO PARTECIPATE TUTTI www.cipomo.it; nicsonet.it LINEE GUIDA AIOM: LA TERAPIA ANTIEMETICA Fausto Roila S.C. Oncologia Medica, Terni
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Antiemetic Therapy Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing Information... 8 References... 8 Effective Date... 1/1/2018
More informationGeriatric Nutrition Assessment for Primary Care Providers
Geriatric Nutrition Assessment for Primary Care Providers July 16, 2008 NRHA Quality and Clinical Conference Esther M. Forti, PhD, RN Vicky J. Ott, MS, RD Funding Source: HRSA Bureau of Primary Health
More informationComparing Different Antiemetic Regimens for Chemotherapy Induced Nausea and Vomiting
Comparing Different Antiemetic Regimens for Chemotherapy Induced Nausea and Vomiting Sayantani Ghosh, Saugat Dey Corresponding author: Sayantani Ghosh (ghoshsayantani@rediffmail.com) Correspondence concerning
More informationFor the Patient: ACTW Other names: BRAJACTW
For the Patient: ACTW Other names: BRAJACTW A Doxorubicin (ADRIAMYCIN ) C Cyclophosphamide T Paclitaxel (TAXOL ) weekly Uses: BRAJACTW is a drug treatment given after breast cancer surgery (called adjuvant
More informationFor the Patient: Bendamustine Other names: TREANDA
For the Patient: Bendamustine Other names: TREANDA Bendamustine (ben'' da mus' teen) is a drug that is used to treat some types of cancer (lymphoma). It is a clear liquid that is injected into a vein.
More informationManagement of Side Effects from Chemotherapy
Management of Side Effects from Chemotherapy Dr. Carol Kwok Clinical Oncologist, Department of Oncology, Princess Margaret Hospital Introduction Chemotherapy is an important modality in cancer treatment.
More informationFor the Patient: UGINETEV Other Names: Treatment of advanced neuroendocrine tumours of gastrointestinal origin (Non-Functional) using Everolimus
For the Patient: UGINETEV Other Names: Treatment of advanced neuroendocrine tumours of gastrointestinal origin (Non-Functional) using Everolimus UGI = Undesignated GastroIntestinal NET = Neuroendocrine
More informationPrevention of chemotherapy induced nausea and vomiting in pediatric cancer patients
REVIEW ARTICLE Prevention of chemotherapy induced nausea and vomiting in pediatric cancer patients Shubham Roy 1, Rashi Kulshrestha 2, Abhishek Shankar 3, Goura Kishor Rath 4, Vipin Kharade 4 1 Department
More information